ATE470153T1 - Diagnostische verfahren für therapeutische verbindungen sowie verfahren zur überwachung der azathioprin-therapie - Google Patents
Diagnostische verfahren für therapeutische verbindungen sowie verfahren zur überwachung der azathioprin-therapieInfo
- Publication number
- ATE470153T1 ATE470153T1 AT04819656T AT04819656T ATE470153T1 AT E470153 T1 ATE470153 T1 AT E470153T1 AT 04819656 T AT04819656 T AT 04819656T AT 04819656 T AT04819656 T AT 04819656T AT E470153 T1 ATE470153 T1 AT E470153T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- azathioprine therapy
- therapeutic compounds
- individual
- monitoring
- Prior art date
Links
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 title abstract 3
- 229960002170 azathioprine Drugs 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title abstract 3
- 238000002405 diagnostic procedure Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000012544 monitoring process Methods 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- OTDJAMXESTUWLO-UUOKFMHZSA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]-3H-purine-6-thione Chemical class C12=NC(N)=NC(S)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OTDJAMXESTUWLO-UUOKFMHZSA-N 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000004043 responsiveness Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52737603P | 2003-12-05 | 2003-12-05 | |
| US11/003,306 US7524851B2 (en) | 2003-12-05 | 2004-12-02 | Diagnostic methods for therapeutic compounds and methods for monitoring azathioprine therapy |
| PCT/EP2004/013842 WO2005054850A2 (en) | 2003-12-05 | 2004-12-06 | Diagnostic methods for therapeutic compounds and methods for monitoring azathioprine therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE470153T1 true ATE470153T1 (de) | 2010-06-15 |
Family
ID=34656405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04819656T ATE470153T1 (de) | 2003-12-05 | 2004-12-06 | Diagnostische verfahren für therapeutische verbindungen sowie verfahren zur überwachung der azathioprin-therapie |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7524851B2 (de) |
| EP (1) | EP1695092B8 (de) |
| AT (1) | ATE470153T1 (de) |
| CA (1) | CA2551010A1 (de) |
| DE (1) | DE602004027534D1 (de) |
| WO (1) | WO2005054850A2 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20050391A1 (it) | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti analoghi della 6-tioguanosina trifosfato, loro uso in campo medico e procedimento per la loro preparazione. |
| WO2010009166A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Oxindolyl inhibitor compounds |
| CA2729909A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Imidazolyl pyrimidine inhibitor compounds |
| US8124764B2 (en) | 2008-07-14 | 2012-02-28 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitor compounds |
| CN102123987A (zh) | 2008-07-28 | 2011-07-13 | 吉里德科学公司 | 亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物 |
| US8283357B2 (en) | 2009-06-08 | 2012-10-09 | Gilead Sciences, Inc. | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds |
| KR20120031170A (ko) | 2009-06-08 | 2012-03-30 | 길리애드 사이언시즈, 인코포레이티드 | 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물 |
| WO2012048106A2 (en) * | 2010-10-06 | 2012-04-12 | Board Of Regents, The University Of Texas System | Biomarkers useful to predict mek inhibitor drug efficacy |
| CN106226414A (zh) * | 2016-07-08 | 2016-12-14 | 黑龙江东方学院 | 利用hplc法测定婴幼儿配方奶粉中核苷酸的方法 |
| CN117074582B (zh) * | 2023-07-14 | 2025-11-11 | 苏州和合医学检验有限公司 | 一种同时检测血液中6种免疫抑制剂浓度的方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6355623B2 (en) | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
-
2004
- 2004-12-02 US US11/003,306 patent/US7524851B2/en not_active Expired - Fee Related
- 2004-12-06 CA CA002551010A patent/CA2551010A1/en not_active Abandoned
- 2004-12-06 WO PCT/EP2004/013842 patent/WO2005054850A2/en not_active Ceased
- 2004-12-06 DE DE602004027534T patent/DE602004027534D1/de not_active Expired - Lifetime
- 2004-12-06 AT AT04819656T patent/ATE470153T1/de not_active IP Right Cessation
- 2004-12-06 EP EP04819656A patent/EP1695092B8/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004027534D1 (de) | 2010-07-15 |
| EP1695092A2 (de) | 2006-08-30 |
| US20050220709A1 (en) | 2005-10-06 |
| US7524851B2 (en) | 2009-04-28 |
| WO2005054850A2 (en) | 2005-06-16 |
| WO2005054850A3 (en) | 2005-11-17 |
| EP1695092B1 (de) | 2010-06-02 |
| EP1695092B8 (de) | 2010-09-22 |
| CA2551010A1 (en) | 2005-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008146309A3 (en) | Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
| DK1597391T3 (da) | Anvendelse af intron-RNA til måling af genekspression | |
| DK1421215T3 (da) | Fremgangsmåder til evaluering af patologiske tilstande under anvendelse af ekstracellulært RNA | |
| WO2008100352A3 (en) | Diagnosis of metastatic melanoma and monitoring indicators of immunosuppression through blood leukocyte microarray analysis | |
| ATE419390T1 (de) | Verfahren zur diagnose von bauchspeicheldrüsenkrebs | |
| EP1578371A4 (de) | Zusammensetzungen und verfahren für die tumor-diagnose und behandlung | |
| EP1639090A4 (de) | Zusammensetzungen und verfahren zur behandlung und diagnose von krebs | |
| BRPI0507442A (pt) | métodos de diagnóstico e tratamento de pré-eclampsia ou eclampsia | |
| EP1898775A4 (de) | System, verfahren und gerät für die navigierte therapie und diagnose | |
| EP2019619A4 (de) | Entzündungserkrankungsprogression, diagnose- und behandlungsüberwachungsverfahren, systeme, gerät und verwendung | |
| EP2522743A3 (de) | Zum Prostatakrebsrisiko beitragende genetische Varianten | |
| WO2008095492A3 (en) | A method for diagnosing atherosclerotic plaques by measurement of cd36 | |
| WO2003083140A3 (en) | Classification and prognosis prediction of acute lymphoblasstic leukemia by gene expression profiling | |
| ATE484231T1 (de) | Vorrichtung für vorhersage von muskel/skelett- erkrankungen | |
| WO2006073682A3 (en) | Diagnostic test | |
| ATE470153T1 (de) | Diagnostische verfahren für therapeutische verbindungen sowie verfahren zur überwachung der azathioprin-therapie | |
| WO2007084397A3 (en) | Processing of slpi by chymase | |
| WO2006055524A3 (en) | Biomarkers for diagnosing schizophrenia and bipolar disorder | |
| WO2011133949A3 (en) | Genetic risk analysis in reward deficiency syndrome | |
| WO2006113245A3 (en) | Methods for measuring glycan levels of proteins | |
| EP1987165A4 (de) | Gene mit einfluss auf die menschliche gedächtnisleistung | |
| ATE480641T1 (de) | Zusammensetzungen, reagenzien, kits und verfahren für die diagnose und behandlung von fettleibigkeit und/oder diabetes | |
| NO20082410L (no) | Biomarkorer for anti-nogo-a antistoffbehandling ved spinalstrengskader | |
| WO2007058968A3 (en) | Gene expression profiles and methods of use | |
| WO2008145701A9 (en) | Method for predicting the outcome of a critically ill patient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |